Mar14

Solid Biosciences Inc. (NASDAQ:SLDB) today announced it has received notification from the U.S. Food and Drug Administration ( FDA ) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.

Marcos and Jesús (9 & 12), Seville, Spain

“I knew what destiny had been written for my children and I was aware that from that moment on, I would spend my life rewriting it.”

—Maria Angeles

Feb28

Solid Biosciences is proud to join the global rare disease community again this year to observe Rare Disease Day

Jan30

Solid Biosciences Inc. (NASDAQ:SLDB), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per share.

Jan25

Solid Biosciences Inc. (NASDAQ:SLDB) today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share, for total gross proceeds of approximately $125,000,000.

A progressive genetic muscle wasting disease

Navigation title: 
What is DMD?
Background video: 
Images: 
Show particles: 
Show print button: 
Nov30

Today we are excited to announce the initiation of our first clinical trial for SGT-001.

Nov30

Phase I/II adaptive clinical trial to evaluate safety and efficacy in ambulatory and non-ambulatory children and adolescents.

Simple Print Button

Background video: 
Show particles: 
Show print button: 

Simple Social Sharing Banner

Background video: 
Show particles: 

Pages

More information about Solid?

Please subscribe to receive our latest news